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Abstract
A permissive site for insertion of heterologous peptide sequences has been identified in the capsid proteins of AAV2. While attempting
to use this site for insertion of a nuclear localization sequence, we have observed a drastic reduction in the yield of DNA-containing particles.
ELISA analysis showed that capsid assembly was modestly affected, whereas genome encapsidation was more profoundly altered, a
phenomenon we did not observed when a RGD peptide was inserted at the same location. Furthermore, the NLS viruses displayed poor
transduction efficiency on HeLa and 293 cells. Altogether, these results indicate that the nature of the peptide inserted at position 587 in
the capsid may have important consequences on both particle formation and infectivity.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Intracellular trafficking and proteasomal degradation of
adeno-associated viral vectors (rAAV) have been recently
recognized as limiting steps for efficient cell transduction
(Douar et al., 2001; Duan et al., 2000). Although the exact
mechanism of virus penetration into the nucleus is still
unknown, we attempted to increase the nuclear targeting of
the viral particle, and thereby improve the gene transfer
efficiency, by inserting a nuclear localizing signal (NLS)
onto the surface of AAV capsid. Based on previous studies,
we chose the insertion site at position 587 in the capsid ORF
(Girod et al., 1999; Wu et al., 2000). This position corre-
sponds to an external loop (loop IV or GH) in the capsid
(Wu et al., 2000; Xie et al., 2002). Moreover, mutational
studies have shown that this region could tolerate amino
acid insertions (Wu et al., 2000). The insertion at this
position of a 14 amino acid peptide containing the RGD
motif allows the generation of rAAV particles with titer
comparable to unmodified particles, while extending their
tropism to resistant cells (Girod et al., 1999). We inserted
in-frame in the cap open reading frame (ORF) at amino acid
position 587 a 13 amino acid sequence containing the SV40
NLS and evaluated the impact of this modification on virus
generation and performances in transferring gene to recip-
ient cells.
Results
We cloned in-frame in the cap gene at amino acid posi-
tion 587 a 13 amino acid (QAGPKKKRKVPQG) sequence
encoding the SV40 large T antigen NLS (PKKKRKV, here-
after named the NLS peptide) (Kalderon et al., 1984). As a
control, we generated a similar construct where the NLS
was inactivated by replacing the lysine at position 3 by a
threonine (PKTKRKV, hereafter named the mutated-NLS
peptide) (Kalderon et al., 1984).
We used the pRGDhelpAAV, bearing the RGD sequence
inserted at position 587 of the Cap ORF as described (Girod
et al., 1999), and the parental plasmid, pLT-AAVhelp, con-
taining the unmodified rep and cap genes as controls. The
NLS sequence was introduced into the pRGDhelpAAV in
place of the RGD sequence using the NgoMIV and Bsu36I
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restriction sites. The generated plasmid was called pRep-
nlsCap. The control plasmid with a mutated-NLS was sim-
ilarly constructed and named pRep-mut.nlsCap.
Insertion of NLS or mutated-NLS peptide reduces viral
particles yield
The ability of generating rAAV particles was evaluated
for pRep-nlsCap by tritransfection in HEK 293 as described
previously (Douar et al., 2001). Cells were transfected with
pXX6 (pAd helper plasmid) (Xiao et al., 1998), pSMD2-
Luc (pAAV vector plasmid), and one of the following
pAAV helpers: pRep-nlsCap, pRep-mut.nlsCap, as a nega-
tive control for the specificity of a nuclear targeting,
pRGDhelpAAV, as a control for the capability of the par-
ticle to bear an insertion at position 587, or pLT-AAVhelp,
as the unmodified positive control for production.
Insertion of the SV40 NLS sequence at position 587 led
to a 60-fold reduction of the DNA- containing particles
yield and the mutated-NLS induced a 28-fold decrease,
when compared to the unmodified parental particles gener-
ated with the pLT-AAVhelp plasmid (Figs. 1A and B show
a typical run of rAAV preparations performed and titered
under the same condition in a single assay). In comparison,
the RGD insertion did not affect particle production. This
indicated that both normal and mutated-NLS peptides in-
serted in the capsid impaired viral particles generation. We
asked whether the insertion of the NLS peptide could alter
capsid protein synthesis and/or their stability during the
course of the production process. The analysis of capsid
proteins in HEK 293 cells 30 h posttransfection was per-
formed by SDS–PAGE and Western blot hybridization. The
expected bands corresponding to VP1, VP2, and VP3 were
detected with the monoclonal antibody B1 (Wistuba et al.,
1997) in all the conditions of production (Fig. 1C). The
level of VP1, VP2, and VP3 proteins synthesis was equiv-
alent for the NLS-particle or its mutated version to that
observed with the pRGDhelpAAV, albeit lower than with
the pLTAAV plasmid. Thus, the insertion of both NLS and
RGD peptides in the capsid sequence at position 587 leads
to a limited decrease of capsid protein synthesis. It is note-
worthy that this did not impair virions formation and yield
in the case of the RGD insertion.
Capsid assembly and genome encapsidation are affected
by both NLS and mutated-NLS peptide
The inefficiency in NLS-particle generation could be
linked to a defect in the capsid assembly process. To rule
out a possible replication problem of rAAV genome, the
amount of replicating rAAV genomes during particle pro-
duction was measured by Southern blot and shown to be
equivalent for all helper constructs tested (data not shown).
An enzyme-linked immunosorbent assay (ELISA) based on
the A20 antibody (Progen GmbH, Heidelberg, Germany),
which recognizes both full and empty assembled particles,
was performed to measure capsid particles in the prepara-
tions shown in Fig. 1. A20 binding is not affected by
insertions at position 587 (Girod et al., 1999; Wobus et al.,
2000) or nearby (Wu et al., 2000). Our results indicated that
the capsid assembly process was reduced four-fold, and
six-fold when the NLS peptide or the mutated-NLS were
inserted at position 587, respectively (Table 1). On the
contrary, RGD capsid assembly was equivalent to the wild-
type (wt) one, indicating that an insertion at this position
does not necessarily result in reduced capsid formation.
Comparing the ratios of the assembled capsids generated
(P) to the genome containing physical particles (pp) titer
gives indication about viral genome packaging efficiency.
Whereas the P/pp ratio was not significantly modified by the
RGD insertion (Table 1), the presence of the NLS peptide
reduced packaging efficiency more than 10-fold and the
mutated-NLS peptide by less than 5-fold (Table 1). These
Fig. 1. rAAV-CMVLuc production yields with the various helper plasmids.
(A) Titers obtained for the productions based on the use of modified and
unmodified helper plasmids (note that pRepCap4 is another helper plasmid
bearing an unmodified cap gene, equivalent to pLT-AAVhelp). Shown here
are the titers of one production and titration assay of five independent
assays performed with each of the modified pRep-nlsCap and pRep-
mut.nlsCap helper plasmids. (B) Dot blot of the productions. Top line:
plasmid range (twofold dilutions from 40 to 0.625 ng). Bottom line: viral
preparations made with the helper plasmids shown in (A). (C) Capsid
protein synthesis during the production of HEK 293 cells. VP1-2-3 were
analyzed by SDS–PAGE and immunoblotting using the B1 antibody (wells
are duplicated). 1–1: nontransfected samples; 2–2: pRC4; 3–3: pLT-
AAVhelp; 4–4: pRGDhelpAAV; 5–5: pRep-nlsCap; 6–6: pRep-
mut.nlsCap. On the right side the molecular weight marker sizes are
indicated, and on the left side the position of the AAV capsid proteins VP1,
VP2, and VP3 are indicated.
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results indicated that this is essentially the encapsidation of
the newly formed viral genomes that is the most severely
affected by the NLS and the mutated-NLS insertions.
Effect of peptide insertions on particle infectivity
Despite their very low production yield, the capability of
cell transduction with these NLS and mutated-NLS particles
was measured. HeLa cells were infected at multiplicity of
infection (m.o.i.) of 500, 2500, and 10,000 physical parti-
cles per cell using viruses generated with the various helper
plasmids. Luciferase gene expression was measured 24 h
later. At an m.o.i. of 2500, the infectivity of the virions on
HeLa and 293 cells was reduced by two to three orders of
magnitude when the NLS or the mutated-NLS were intro-
duced at position 587 of the Cap proteins, even in the
presence of adenovirus (Fig. 2). In the same conditions, the
RGD insertion also reduced the infectivity by 10- to 100- fold. These results indicated that introduction of a peptide at
this position is detrimental for AAV infectivity.
A possible reason for our observations was that the high
number of NLS peptides on the capsid surface impaired the
assembly process or destabilized the newly assembled par-
ticles more than its sequence itself. We therefore produced
rAAV particles bearing decreasing NLS residues on their
surface by mixing the helper plasmids pRep-nlsCap and
pLTAAV help at ratios (pRep-nlsCap/pLTAAVhelp) rang-
ing from 2 to 50%. The level of rAAV generated by this
process decreased proportionally to the increase of NLS
containing capsid proteins (Fig. 3A), consistent with our
previous observation. Moreover, transduction of HeLa cells
with 20,000 and 50,000 pp/cell showed that the more NLS
on their surface, the less infectious the particles. At these
m.o.i. and in the presence of 25% of NLS peptides on the
viral surface, transduction is reduced three to four times
(Fig. 3B). In addition, this decrease (66 to 75% of unmod-
ified particles) suggests that the preparation was indeed
composed of mixed particles bearing both NLS and wild-
type subunits rather than separate populations of particles,
in which case we would have expected a transduction loss
Table 1
Capsid assembly and viral genome packaging
P in % of
rAAV control
pp in % of
rAAV control
P/pp
rAAV 100 100 1.36  0.05a
rAAV RGD 215 140 2.35  0.94a
rAAV NLS 25.7 1.6 14.21  7.36a
rAAV NLS mut. 15.7 3.5 5.59  1.29b
Note. rAAV refers as the particles generated with the pLT-AAVhelp
plasmid (unmodified capsid). The assembled capsids (P) and DNA con-
taining particles (pp) are expressed as percentages of those obtained with
the pLT-AAVhelp plasmid. The capsid (P) titer was determined by an
ELISA assay and the pp titer was determined by dot blot hybridization.
a n  3 assays.
b n  2 assays.
Fig. 2. Transduction of HeLa and 293 cells with the modified and unmod-
ified viruses. The rAAV-CMVLuc produced and shown in Fig. 1 were used
to infect HeLa and 293 cells at an m.o.i. of 2500 pp/cell in the presence or
absence of Ad5 (m.o.i. 1). After 24 h, cells were lysed and assayed for
luciferase activity. Each point within an assay was done in triplicate. The
level of expression is expressed as light units (1 RLU  10 photons) per
second per well. All the values are given as RLU/s/well. Values are given
with the standard deviation (n  3). NI; noninfected.
Fig. 3. rAAV-CMVLuc production yields with increasing ratios of pRep-
nlsCap and pLTAAVhelp helper plasmids. (A) Dot blots of the productions
showing on the right side the plasmid range (ng) and on the left side the
signals from the rAAV made with 0, 25, and 50% (top) and 0 to 20%
(bottom) of pRep.nlsCap. (B) HeLa cells infected at an m.o.i. of 20,000 or
50,000 pp/cell of rAAV-CMVLuc with none (0%) or 25% NLS peptides.
After 24 h, cells were lysed and assayed for luciferase activity. Values are
given with the standard deviation (n  3). NI, noninfected. (C) Binding
analysis of the modified rAAV on HeLa cells. Cells were chilled on ice for
30 min, infected at an m.o.i. of 1000, and incubated for an additional 90
min at 0°C. After three washes with cold DMEM, cells were lysed and
surface-bound virus was released by three freeze/thaw cycles. Viral content
was isolated and quantified by dot blot analysis. Values representing
duplicate points are expressed as the percentage of binding obtained with
the rAAV bearing the wt (unmodified) capsid.
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of only 25%. Furthermore, binding experiments (see below)
are also in favor of mixed particles generation.
We next assayed whether the NLS and mutated-NLS
virions had a reduced stability. The NLS-vectors displayed
no increased sensitivity to heat treatment (56°C for 30 min)
prior to infection relative to the unmodified particles (not
shown). In addition, we checked whether an increased rate
of degradation of the NLS-particles by the ubiquitin-protea-
some proteolytic pathway following their internalization
into the cell was responsible for the loss of infectivity.
Treatment of the target cells with the proteasome inhibitor
MG132, as described previously (Douar et al., 2001), en-
hanced gene transfer in the same extent for modified and
unmodified particles (not shown). Therefore, the decrease in
transduction efficiency was neither due to heat instability of
the virus nor to increased proteasomal degradation.
We then analyzed the capability of the NLS-particles to
bind properly at the surface of the target cells. Binding
experiments based on a quantitative dot blot assay (Walters
et al., 2001) were performed on HeLa cells infected with the
NLS- and RGD-modified or unmodified particles at an
m.o.i. of 1000 genome particles per cell. In both cases, the
binding capability of the modified particles was deeply
affected, the NLS- and RGD-modified particles depicting
none and 2% residual binding, respectively (Fig. 3C). More-
over, the decrease of cell binding paralleled the increase of
NLS residues on the viral particle (Fig. 3C). It is noteworthy
that the decrease in binding capability is stronger than
expected from the amount of NLS residues alone. This
confirms the presence of mixed viral particles, but also
suggests a transdominant negative effect of the inserted
NLS peptide. These results are consistent with recent data
suggesting that the region surrounding amino acid 587 is
important for cell transduction (Grifman et al., 2001).
Discussion
The identification of a permissive site for peptide inser-
tion in the capsid proteins of AAV2 (Girod et al., 1999) has
open the possibility of targeting recombinant viral vectors to
heterologous receptors, or to enhance their intracellular traf-
ficking performances. Here, we have inserted a NLS peptide
at position 587 (I-587) of the capsid sequence and observed
two distinct deleterious effects, one affecting virion forma-
tion, the other altering infectivity of the viral particle. First
we noticed a peptide-dependent alteration of virus forma-
tion, essentially affecting the assembly and packaging steps.
We observed a 10-fold drop of packaging efficiency with
the NLS-capsid, while normal packaging occurred with the
RGD-capsid, as previously reported (Girod et al., 1999).
These observations imply that in the attempts to modify
viral tropism and targeting, not only the insertion site may
affect particle generation (Girod et al., 1999; Grifman et al.,
2001; Rabinowitz et al., 1999; Shi et al., 2001; Wu et al.,
2000), but also the inserted peptide has a specific effect as
well. Such effect has been recently described in relation to
receptor binding capability (Shi et al., 2001). Packaging of
the viral genome occurs in a precise spatial and temporal
order within the nucleus and involves the Rep proteins
(Dubielzig et al., 1999; King et al., 2001; Wistuba et al.,
1997). It is possible that the presence of the SV40 NLS
peptide in VPs, and in a lesser extent its mutated version,
but not the RGD, has altered the correct process, schedule,
and location of viral genome packaging.
Our second observation is a drastic reduction of infec-
tivity of the all insertion mutants (NLS, mutated-NLS, and
RGD). We showed by binding studies that insertion of three
different peptides at position 587 of the capsid sequence
profoundly altered the binding capability of the viral parti-
cles. These results confirm previous observations suggest-
ing that this region is involved in cell attachment. Inser-
tional mutagenesis studies have recently shown that the
binding to HSPGs, the primary receptor for AAV, was
partially altered by insertion at position 587 of the cap ORF
(Shi et al., 2001) and partially defective mutants were ob-
tained following insertions in the region spanning between
amino acids 561 and 591 (Wu et al., 2000). In addition,
Girod et al. also observed a drop to 0.5% of infectivity of
their I-587 mutant, which they attributed to a reduced bind-
ing to the cell membrane or an altered transport toward the
nucleus (Girod et al., 1999). Finally, the recently resolved
crystal structure of AAV2 particle has allowed to unam-
biguously localize the primary attachment region of AAV2
in the GH loop (Xie et al., 2002). The heparan binding motif
is an amino acid sequence of XBBBXXBX, where B is a
basic amino acid and X is any amino acid (Hileman et al.,
1998). Because of the high level of basic residue in the NLS
sequence, we had expected that the peptide would not alter
too profoundly the binding of the particles to the cell-
surface HSPGs. However, it appears that the integrity of the
region surrounding position 587 is required for optimal
infectivity of the particles through binding to their cellular
receptor.
Materials and methods
Plasmid construction
The pRGDhelpAAV was derived from the pLTAAV
(unmodified AAV helper plasmid) and contains an RGD
motif framed by the NgoMIV and Bsu36I restriction sites at
amino acid position 587 of the cap ORF, as described
(Girod et al., 1999). To generate the pRep.nlsCap, two
complementary primers containing the NLS sequence and
the open above restriction sites were annealed (5 primer:
ccggcccaaaaaagaagagaaaggtacc; 3 primer: gggttttttcttctctt-
tccatggagt) and ligated in place of the RGD motif into the
pRGDhelpAAV. The control plasmid, pRep-mut.nlsCap,
bearing the K-to-T substitution, was similarly constructed
(5 primer: ccggcccaaaaacgaagagaaaggtacc; 3: gggtttttgct-
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tctttccatggagt). The pSMD2-Luc plasmid, used to generate
rAAV-CMVLuc, was described elsewhere (Douar et al.,
2001). Modified plasmids were sequenced around the clon-
ing region for conformity using an ABI Prism DNA se-
quencer 577 (PE Biosystems).
rAAV preparation
rAAV were prepared as described previously (Douar et
al., 2001). Briefly, two 150-mm plates of HEK 293 cells
were triple transfected by the pXX6 and pSMD2-Luc plas-
mids, and one of the pAAV-helper plasmids: pLTAAV,
pRep.nlsCap, pRep-mut.nlsCap, as a control for the nature
of the insertion, or pRGDhelpAAV, as a control for the
modification at position 587. The crude lysates were frozen
and thawed four times, treated with benzonase, and directly
used for assays. Physical particles were estimated by dot
blot (Snyder et al., 1996). For each modified plasmid
(pRep.nlsCap and pRep.nls-mut.Cap) we generated five in-
dependent preparations and reproducibly observed de-
creased titers in the same extent (with pRep.nlsCap 6.54 
109  2.19 109 pp/ml and with pRep.nls-mut.Cap 1.10
1010  6.41  109 pp/ml). In Fig. 1, the results shown
correspond to one typical production assay. These rAAV
preparations were performed and titered within a single
assay and were used for all the subsequent studies. In
comparison, usual preparation of this scale with the
pLTAAV yields 5 to 10  1011 pp/ml.
Cell transduction and luciferase assay
HeLa cells seeded in six-well plates were infected at the
indicated m.o.i. (pp per cells) and further incubated for 24 h.
Luciferase gene expression was measured as described pre-
viously (Douar et al., 2001). Briefly, cells were lysed in 250
l lysis buffer (Tris–phosphate 25 mM; DTT 1 mM, EDTA
1 mM; glycerol 15%; MgCl2 8 mM; 0.2% Triton X-100) for
10 min. Fifty microliters of the lysate was mixed to 100 l
of assay buffer (Tris–phosphate 25 mM; DTT 1 mM; EDTA
1 mM; glycerol 15%; MgCl2 8 mM; ATP 2 mM) and 100 l
luciferin 167 M (Molecular Probes). The relative light
units (RLU) were measured with a luminometer (Mediators
Diagnostika) for 10 s. Each point within an assay was done
in triplicate. Each assay was performed at least two times.
The level of expression is expressed as relative light units
per second per well (RLU/s/well).
SDS–PAGE and immunoblotting
Small-scale productions in six-well plates were per-
formed in duplicate as follows: 2  106 HEK cells were
transfected with 1.7 g of pXX6, 1 g of pSMD2Luc, and
1 g of the AAV helper plasmid for 6 h. Following medium
change, the production process was allowed to continue for
24 h. Proteins were extracted by adding 350 l luciferase
lysis buffer supplemented with protease inhibitors. Samples
were resuspended in 40 l Laemmli buffer 1 (Sigma)
supplemented with 5% -mercaptoethanol and then heat-
denatured. Proteins were separated by 10% SDS–PAGE and
electrotransferred on a nitrocellulose membrane. Detection
of AAV VP1, VP2, and VP3 was done by hybridization
with the B1 monoclonal antibody (Wistuba et al., 1997)
overnight at 4°C, followed by a horseradish peroxidase
conjugated secondary antibody 10,000-fold diluted. The
level of capsid protein synthesis was monitored with the
ECL detection kit (Amsersham).
AAV capsid assembly assay
ELISA based on the A20 antibody (Grimm et al., 1999)
was done with precoated plates as described by the manu-
facturer (Progen GmbH). The A20 antibody detects fully
assembled particles.
Cell binding assay
Viral binding assay was performed as described (Walters
et al., 2001). Briefly, HeLa cells seeded in a 48-multiwell
plate were chilled on ice for 30 min, then infected at an
m.o.i. of 1000, and further incubated for 90 min at 0°C.
Cells were washed with cold DMEM and frozen and thawed
to release cell-surface-bound virus. Viral content was iso-
lated as for the titration (Snyder et al., 1996) and quantified
by dot blot and radioactive hybridization with a probe spe-
cific for the transgene sequence. Membranes were scanned
on a PhosphorImager (Molecular Dynamics). Specific sig-
nals were quantified with the Image Quant software (Mo-
lecular Dynamics).
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